Search
2025
2024
2023
-
Sep 11, 2025
YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICCRead More
-
Jul 28, 2025
YOLT-203 Receives Orphan Drug Designation from EMARead More
-
Jul 14, 2025
YolTech Therapeutics Announces NMPA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)Read More
-
Jun 27, 2025
Prof. Michael Ott Joins YolTech as Scientific AdvisorRead More
-
Jun 06, 2025
YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)Read More
